Marksans Pharma board to meet on May 26, 2026, to approve audited financial results for Q4 and FY ending March 31, 2026.
Board will consider recommending a dividend for FY 2025-26, subject to their decision.
Trading window for designated persons closed from April 1, 2026, until May 28, 2026, due to insider trading regulations.
Intimation filed under SEBI LODR Regulation 29 and is available on company and exchange websites.